达利雷生一次能囤几盒?多少钱?

DaliRasen is a new type of dual orexin receptor antagonist. Its purchase quantity is restricted by regional regulatory policies, drug circulation rules and actual patient needs. The amount of medicine stocked at a time usually does not exceed 3 boxes. Drug prices vary significantly depending on specifications, production countries and purchasing channels.

How many boxes of DaliRasen can be stocked at a time

The number of medicines to be stocked is limited by three factors: drug circulation regulatory policies, actual patient needs, and drug storage conditions. Patients need to balance treatment continuity and medication safety within the legal and compliance framework.

Regional regulatory policy constraints

Although Hong Kong, China has approved the marketing of DaliRasen, individuals carrying prescription drugs into the country must hold both a doctor's prescription and a pharmacy invoice, and the amount carried at a time must not exceed 3 months' therapeutic dosage. Based on the 50 mg dosage once a day, the maximum amount of medicine stored at a time does not exceed 90 tablets (approximately 4.5 boxes).

Mainland China has not yet approved the drug for marketing. When patients purchase through cross-border drug purchasing platforms, they must abide by the regulations on a reasonable quantity for personal use. The platform usually sets a single purchase limit of 3 boxes.

Restrictions on drug storage conditions

DaliRasen needs to be stored at a constant temperature of 20-25°C. If the patient stores more than 3 boxes of medicine, a special medicine refrigerator is required. Japan’s Ministry of Health, Labor and Welfare recommends that household medicine storage should be controlled within 30 days to avoid drug failure due to improper storage.

Dynamic assessment of treatment needs

Insomnia treatment requires an efficacy evaluation every 2 weeks, including Pittsburgh Sleep Quality Index (PSQI) score and Daytime Impairment Scale (SDS) testing. If the patient's PSQI score decreases by less than 30%, the medication regimen needs to be adjusted in a timely manner. At this time, stocking up on medication may lead to a waste of resources.

How much does DaliRasei cost?

The price system of DaliRasei is significantly affected by specifications, production countries and purchasing channels. Patients need to choose a purchasing plan based on their financial ability, medication cycle and medical insurance policy.

Original drug price

DaliRasen (50 mg × 20 tablets) produced in Alschwil, Switzerland, is priced at approximately US$404 per box. This price includes R&D cost sharing, EU GMP certification fees and cold chain transportation costs.

The impact of medical insurance policies on prices

DaliRasan has not yet been included in the medical insurance catalog of any country in the world, and patients need to pay the full amount out of pocket. However, some commercial insurance companies provide drug benefit plans and provide 30% cost reduction to qualified patients.

Usage of DaliRasen in special populations

The use of DaliRasen in special populations must strictly follow the dosage adjustment principle to avoid treatment interruption or adverse reactions due to metabolic differences or organ function damage.

Drugs during pregnancy and lactation

Animal experiments have shown that no fetal malformation occurred when pregnant rats were orally administered dalirasant to 10 times the maximum recommended dose of 50 mg during the organ formation period. However, there is still no data on drug use during human pregnancy, and the U.S. FDA classifies it as a Category C pregnancy drug. Concentrations of daliramin in the breast milk of lactating women are extremely low, but the infant's sedation response needs to be monitored.

Use by the elderly and those with liver and kidney dysfunction

Patients over 65 years old do not need to adjust the dose, but they need to be alert to the risk of drowsiness. Japanese clinical data shows that the incidence of falls in this group is 2.3 times higher than that of younger patients. The maximum recommended dose for patients with moderate hepatic impairment (Child-Pugh score 7-9) is 25 mg, and it is contraindicated for patients with severe hepatic impairment (Child-Pugh score ≥ 10). Patients with renal insufficiency do not need to adjust the dosage, but they need to check the blood drug concentration every 3 months to avoid respiratory depression due to drug accumulation.

Usage in children and patients with respiratory diseases

The safety and effectiveness of the drug have not been established for adolescents under 18 years old, and the US FDA prohibits its use by this group. Patients with obstructive sleep apnea syndrome (OSAS) need to use continuous positive airway pressure (CPAP) on the basis of treatment to avoid a decrease in blood oxygen saturation due to respiratory drive suppression.

Patients with chronic obstructive pulmonary disease (COPD) need to increase the frequency of blood oxygen saturation monitoring from once a day to three times a day after use.